MONEY

Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC at ESMO 2024

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 15, 2024 - 16:00
Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC at ESMO 2024
Read More

Tags:

Previous Article

Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-P...

Next Article

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

UPDATE - MedCerts Launches Certified Nursing Assistant (CNA) eLearning Program Benefiting Medical Providers, Patients and Aspiring Healthcare Professionals

UPDATE - MedCerts Launches Certified Nursing Assistant ...

Tomas Kauer - Mode... Sep 24, 2024

Oaktree Acquisition Corp. III Life Sciences Announces Pricing of $175 Million Initial Public Offering

Oaktree Acquisition Corp. III Life Sciences Announces P...

Tomas Kauer - Mode... Oct 24, 2024

Sprouts farmers market CEO sells over $1.29 million in stock

Sprouts farmers market CEO sells over $1.29 million in ...

Tomas Kauer - Mode... Oct 9, 2024